Nucana (NCNA) AI Stock Analysis

1,742 Followers

Nucana

(NASDAQ:NCNA)

Select Model

Rating:38Underperform

Price Target:$0.88▼(-6.01% Downside)

Action:reiterated

Date:11/15/26

The overall score is very weak, driven primarily by a fundamentally unsound financial position with no revenue and ongoing cash burn, compounded by a bearish technical trend across all timeframes. The company's survival depends on successful capital raises and future drug development, both highly uncertain.

Positive Factors

Low leverageVery low leverage limits balance-sheet debt risk and preserves financial flexibility while the company advances its pipeline. With minimal debt obligations, future financing and capital-allocation decisions are less constrained by interest costs or mandatory repayments.

Negative Factors

No reported revenueThe absence of revenue means NuCana has not yet demonstrated commercial demand or an operating model that funds itself. Until a candidate reaches commercialization, financial performance remains tied to clinical progress and the company’s ability to finance continued development.

Nucana (NCNA) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $5.66M
Dividend Yield: ―
Average Volume (3M): 115.93K
Price to Earnings (P/E): -0.2
Beta (1Y): 1.42
Revenue Growth: ―
EPS Growth: 97.82%
Country: US
Employees: 11
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Nucana Business Overview & Revenue Model

Company Description

NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is pro...

Nucana Financial Statement Overview

Summary

Nucana is a pre-revenue biotech with zero revenue and persistent net losses. While cost control has improved, the complete lack of income and negative margins make this the weakest possible financial profile. The balance sheet shows low debt but rapidly eroding equity, and cash flow remains deeply negative despite a reduced burn rate.

Income Statement

1Very Negative

Balance Sheet

55Neutral

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Mar 2022
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	-140.82K	0	0	0	0	0
EBITDA	-12.49M	-20.56M	-22.48M	-30.55M	-42.98M	-44.42M
Net Income	-11.04M	-29.35M	-19.00M	-27.63M	-32.02M	-40.53M
Balance Sheet
Total Assets	24.58M	29.83M	14.77M	27.81M	58.25M	77.47M
Cash, Cash Equivalents and Short-Term Investments	18.47M	24.25M	6.75M	17.23M	41.91M	60.26M
Total Debt	668.45K	676.00K	190.00K	396.00K	639.00K	371.00K
Total Liabilities	4.89M	5.51M	8.82M	12.92M	19.75M	11.93M
Stockholders Equity	19.69M	24.33M	5.95M	14.89M	38.50M	65.55M
Cash Flow
Free Cash Flow	-7.89M	-7.66M	-19.41M	-26.92M	-23.68M	-24.89M
Operating Cash Flow	-7.76M	-7.47M	-19.12M	-26.44M	-23.16M	-23.82M
Investing Cash Flow	123.24K	159.00K	79.00K	2.89M	120.00K	-3.56M
Financing Cash Flow	457.48K	25.01M	8.18M	-53.00K	-161.00K	-98.00K

Nucana Technical Analysis

Technical Analysis SentimentNegative

Last Price0.93

Price Trends

50DMA1.13Negative

100DMA1.27Negative

200DMA1.64Negative

Market Momentum

MACD-0.05Negative

RSI36.83Neutral

STOCH25.11Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NCNA, the sentiment is Negative. The current price of 0.93 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 1.13, and below the 200-day MA of 1.64, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 36.83 is Neutral, neither overbought nor oversold. The STOCH value of 25.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NCNA.

Nucana Risk Analysis

Nucana disclosed 92 risk factors in its most recent earnings report. Nucana reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.Q4, 2023

2.Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer cybersecurity incidents, which could result in a material disruption of our product development programs, and could subject us to liability.Q4, 2023

3.Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.Q4, 2023

Nucana Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

NCNA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APRE	49Neutral	$5.91M	-0.59	-44.26%	―	-99.32%	67.31%
XBIO	46Neutral	$3.89M	-1.05	-58.96%	―	3.50%	22.76%
IMRN	44Neutral	$8.09M	-2.87	-31.88%	―	10.41%	42.44%
NCNA	38Underperform	$4.49M	-0.24	-51.04%	―	―	97.82%

* Healthcare Sector Average

Performance Comparison

NCNA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
NCNA	Nucana Plc	0.93	-2.27	-70.88%
XBIO	Xenetic Biosciences, Inc.	1.66	-0.83	-33.33%
IMRN	Immuron	0.88	-0.69	-43.91%
APRE	Aprea Therapeutics, Inc.	0.42	-0.77	-65.04%

Nucana Corporate Events

NuCana Announces Third-Quarter 2026 Financial Results

Nov 12, 2026

NuCana plc is a foreign issuer with principal executive offices in Edinburgh, United Kingdom. On November 12, 2026, the company issued a press release announcing its third-quarter 2026 financial results, including unaudited condensed consolidated fin...

NuCana Wins Key European Patent for Lead Cancer Drug NUC-7738

Sep 30, 2026

NuCana plc, a clinical-stage biopharmaceutical company based in Edinburgh, develops cancer therapies using its proprietary ProTide technology to enhance existing nucleoside analog chemotherapy agents. Its lead candidates include NUC-7738, a novel ant...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 15, 2026

Nucana AI Stock Analysis